I nfection is one of the leading complications of intravascular catheters and is associated with increased mortality, prolonged hospitalization, and increased medical costs. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Central venous catheters (CVCs) account for an estimated 90% of all catheterrelated bloodstream infections (CRBSIs).
Several risk factors have been documented for CVC-related infections, which include very importantly the duration of catheterization, [15] [16] [17] [18] [19] [20] location of the catheter (internal jugular vein greater than subclavian vein), use of parenteral nutrition, use of multilumen Central venous catheters (CVCs) are extensively used worldwide. Mechanical, infectious and thrombotic complications are well described with their use and may be associated with prolonged hospitalization, increased medical costs and mortality. CVCs account for an estimated 90% of all catheter-related bloodstream infections (CRBSI) and a host of risk factors for CVC-related infections have been documented. The duration of use of CVCs remains controversial and the length of time such devices can safely be left in place has not been fully and objectively addressed in the critically ill patient. Antimicrobial-impregnated catheters have been introduced in an attempt to limit catheter-related infection (CRI) and increase the time that CVCs can safely be left in situ. Recent meta-analyses concluded that antimicrobial-impregnated CVCs appear to be effective in reducing CRI. The authors conducted a prospective, randomized, double-blind study at Johannesburg Hospital over a 4year period. The study entailed a comparison of standard triple-lumen versus antimicrobial impregnated CVCs on the rate of CRI. Our aim was to determine whether we could safely increase the duration of catheter insertion time from our standard practice of seven days to 14 days, to assess the influence of the antimicrobial impregnated catheter on the incidence of CRI, and to elucidate the epidemiology and risks of CRI. One hundred and eighteen critically ill patients were included in the study which spanned 34 951.5 catheter hours (3.99 catheter years). It was found that antimicrobial catheters did not provide any significant benefit over standard catheters, which the authors feel can safely be left in place for up to14 days with appropriate infection control measures. The most common source of CRI was the skin. The administration of parenteral nutrition and the site of catheter insertion (internal jugular vein vs subclavian vein) were not noted to be risk factors for CRI. There was no clinical evidence of thrombotic complication in either of the study groups. This study offers direction for the use of CVCs in critically ill patients and addresses many of the controversies that exist.
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catheters (increased manipulation), experience of personnel inserting the device, less stringent barrier precautions during placement, type of dressing, presence of sepsis, catheter care after placement, and presence of CVC-related thrombi. [19] [20] [21] [22] The duration of use of CVCs remains controversial, and the length of time they can safely be left in place has not been fully and objectively addressed in the critically ill patient. 23, 24 During the past few years antimicrobialimpregnated catheters have been introduced in an attempt to limit catheter-related infection (CRI) and increase the time that CVCs can safely be left in situ. A recent meta-analysis concluded that chlorhexidinesilver sulfadiazine (CSS) CVCs appear to be effective in reducing CRI, 25 and 2 other meta-analyses have reached similar conclusions. 26, 27 The aims of this study were to determine whether we could safely increase the duration of CVC insertion time from our standard practice of 7 days to 14 days, to assess the influence of an antimicrobial-impregnated catheter on the incidence of CRI, and to elucidate the epidemiology and various risks of CRI in a population of critically ill patients, including clinically evident catheter-related thrombosis.
Materials and Methods
This was a prospective, randomized, double-blind study performed in the adult multidisciplinary intensive care unit (ICU) at Johannesburg hospital, Johannesburg, South Africa between 1996 and 1999. The study included 118 critically ill medical, surgical, trauma, and obstetric/gynecological patients, and entailed comparison of the rate of CRIs for a 14-day placement of standard triple-lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA) versus antimicrobial-impregnated (CSS; ARROWgard Triple Lumen Catheter, Arrow International Inc, Reading, PA) CVCs.
The 2 types of catheters were of identical appearance and were subsequently differentiated by a numerical code, which was broken only on completion of the study. The randomization protocol involved equal numbers of the 2 types of nondistinguishable catheters being mixed in consignments and then selected in a consecutive fashion for placement in study candidates.
Exclusion criteria for the study were age less than 18 years, white blood cell count on admission of less than 4 × 10 9 /L, skin burns, and a history of allergy to sulfa-containing preparations. No guide wire exchanges were performed.
Standard infection control measures were practiced with catheter insertion. This included handwashing, the use of sterile gowns, sterile gloves, full sterile drapes, masks, and caps. The catheters were placed by the ICU medical staff, including intensivists, fellows, and residents in training, into the right-or left-subclavian or internal jugular veins as judged most appropriate by clinical evaluation.
Skin swabs were taken for culture prior to cleansing and catheter insertion. The skin insertion site was cleansed with a 0.5% chlorhexidine-gluconate in 70% alcohol solution. Catheters were inspected and dressed daily, and a clinical assessment undertaken for any evidence of catheter-related thrombosis. The catheters were studied for colonization and CRBSI at removal. The origin of each CRBSI was sought by culturing all potential sources (skin, catheter segments, hubs, and infusate). A semiquantitative culture was performed on the catheters, using the roll-plate technique as described by Maki et al. 28 DNA molecular typing was used to assist in microbiological analyses. All relevant clinical data were collected and evaluated.
CRI was defined according to the criteria proposed by the Centers for Disease Control and Prevention. 29 Definitions for identifying the source of an isolate causing a CRBSI are shown in Table 1 . Catheters remained in place until they were no longer required, a specific event necessitated removal, or for 14 days, whichever occurred first. All existing intravascular catheters were removed prior to insertion of the study catheters. Any parenteral nutrition administered was delivered via a single dedicated port. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . No statistically significant differences between the 2 catheters could be demonstrated in terms of number of days of catheter placement (p = 0.3341) and colonization, or BSI (13/62 vs 10/56) versus no infection (P = .6704; see Table 3 ). Furthermore, no statistically significant difference in CRBSI or colonization between the 2 catheters could be demonstrated for removal at or before 7 days (P = .6003) and after 7 days (P = 1.000).
The site of CVC insertion (internal jugular vein vs subclavian vein), the administration of parenteral nutrition, and BSI at the time of catheter insertion were not noted to be risk factors for catheter infection (P = .1617, .5449, and .4575). In addition, no statistical difference could be demonstrated between the 2 catheters for these variables (P = .3320, .5868, and .1861). A significantly greater number of patients had an internal jugular vein insertion site (95 vs 23; P < .0001).
The most common source of primary CRBSI was skin, followed by hub and infusate. There was no statistical difference between the 2 catheters. The most common microorganism isolated as a cause of CRBSI was coagulase-negative Staphylococcus. Other microorganisms associated with CRBSI included Staphylococcus aureus and various gram-negatives such as Serratia marcescens, Klebsiella pneumoniae, Enterobacter aerogenes, Acinetobacter baumanii, Providencia species, and Alkaligenes faecalis. A yeast was identified in 1 case (CSS catheter). Primary CRBSI occurred in 9 cases with a standard catheter and in 6 cases with a CSS catheter. There were no significant differences between the catheters in terms of the nature of the microorganisms causing CRBSI. Similarly, with respect to colonization, there were no significant differences in the nature of the colonizing bacteria between the 2 catheters. Coagulase-negative Staphylococci were the most commonly isolated colonizer involving 3 catheters (2 standard catheters, 1 CSS), with E cloacae (standard CVC) and Bacillus cereus (CSS CVC) being the other 2 colonizers.
No statistically significant differences were noted in the number of bacteria colonizing the skin around the CVC insertion site both prior to catheter insertion and at the time of catheter removal on analysis of colony forming units of isolates (p = 0.08). Coagulase-negative Staphylococci constituted the majority of 161 skin colonizers that were isolated (60%). Other bacteria isolated from the skin cultures in descending order of frequency included Enterobacteriaceae (10%), Bacillus species (7.5%), A baumanii (5%), S aureus (4%), enterococci (4%), diptherioids (4%), Pseudomonas species (3%), and Streptococcus species (2.5%). For each of these microorganisms, there were no statistically significant differences between isolates when comparing the 2 types of catheters (p > 0.05).
No significant noninfectious complications such as pneumothorax related to catheter placement were documented. There was no clinical evidence of catheterrelated thrombosis in either of the study groups.
Discussion
In this study, we examined the influence of antimicrobial-impregnated CVCs on the incidence of CRI and whether CVCs can safely be left in place for a period of up to 14 days; we also elucidated the epidemiology and risks (such as insertion site, clinical evidence of thrombosis, and the use of parenteral nutrition) of CRI in a population of critically ill patients.
Exactly how long noncuffed short-term CVCs can safely be left in place, particularly in critically ill patients, has not been previously assessed. 23, 24 In general, most studies that have evaluated the duration of placement as a risk factor have shown that prolonged placement significantly increases the cumulative risk of infection, particularly if it is longer than 5 to 7 days. [30] [31] [32] [33] [34] Indeed, a critical review of well-designed published studies of risk factors for CVC-related BSIs revealed that duration beyond 7 days was associated with a significantly increased risk of CRBSI. 23 Despite suggestions that routine replacement of CVCs at short-term intervals such as every 4 to 5 or 7 days may not significantly reduce the risk of CVC-related BSI in patients requiring prolonged central access, this has not been conclusively established. 20 Although some studies report no decline in the incidence with routine replacement, most have not had sufficient statistical power to answer this question. 23 Because the issue of "safe" duration of catheter retention has remained controversial and unanswered, 23 scheduled replacement is still widely practiced in many ICUs, despite currently available guidelines and recommendations. In a study in mainland Britain where 165 ICUs were surveyed, catheters were routinely replaced in the majority, the mean time being 6.5 days. 35 We believe that this study with almost 35 000 hours of catheter dwell time provides an ample basis to advocate "safe" CVC dwell time and also offers suitable direction. The need for an intravascular catheter should, however, be frequently assessed, and the device should be removed as soon as the intended use is over. 36 During the past several years, antimicrobialimpregnated CVCs have been introduced in an attempt to limit CRI and increase the time that CVCs can safely be left in situ. Several studies and meta-analyses have reported the benefit of these CVCs in the prevention or reduction of CRI. 26, 27, [37] [38] [39] Cost-efficacy has also been claimed. 40, 41 On the basis of these data, various advisory panels and authorities have recommended the use of antimicrobial-impregnated CVCs in selected clinical settings. 30, 39, [42] [43] [44] [45] [46] However, their role remains controversial, with various workers suggesting that more work is required to support or refute the hypothesis that they may reduce the rate of or prevent CRBSI. 47, 48 A recent review of 11 randomized studies failed to demonstrate any significant clinical benefit associated with the use of antimicrobial-impregnated CVCs for the purpose of reducing CRBSI or improving patient outcome. 47 Concern about the emergence of antimicrobial resistance with the long-term use of these catheters has also been expressed. 42, 44, [47] [48] [49] [50] [51] In this study, we were unable to demonstrate any benefit of an antimicrobial-impregnated catheter (CSS) over standard catheters in critically ill patients. Of interest, there was no difference in colonization or BSI rate between the 2 catheters prior to or after 7 days, which appears to refute the contention that antimicrobialimpregnated catheters may be of particular value. Furthermore, a significantly larger number of trauma patients received a standard catheter, a variable recognized to potentially increase the rate of CRI.
Placement of CVCs in the internal jugular or femoral vein rather than the subclavian vein has been associated with a significantly increased risk of CRBSI. 23 The subclavian vein is currently recommended as the preferred site of placement of CVCs in several guidelines and reviews. 23, 39, 52 Several studies, including 1 randomized clinical trial, have found that percutaneous placement of a CVC in an internal jugular or femoral vein is associated with a substantially higher risk of CRBSI than subclavian vein placement. 15, 23, [53] [54] [55] [56] It has been postulated that internal jugular vein placement may be associated with greater rates of CRI because of possible contamination from oronasal and airway secretions, a higher incidence of CVC-related thrombosis, and difficulty in adequately securing the catheter.
In this study, we were unable to demonstrate any difference in catheter infection related to the site of CVC insertion when comparing internal jugular vein versus subclavian vein placement. This was despite the fact that a significantly greater number of patients had an internal jugular vein insertion site. There was also no statistical difference when comparing the standard versus CSS-impregnated catheters.
Similarly, it has also been well documented that the use of parenteral nutrition is a risk factor for CRBSI with noncuffed percutaneously inserted CVCs. 23, 57 In this study, the administration of parenteral nutrition via a single dedicated port was not noted to be a risk factor for catheter infection, and again, there was no statistical difference between the 2 types of catheters.
Patients with CVCs in situ have previously been reported to be at high risk for catheter-related thrombosis, especially if the catheter has been in place for 1 week or more. 19, 20, 58 It is of particular relevance that the risk of CRI has been strongly correlated to the presence of catheter-related thrombi. [19] [20] [21] [22] The risk of catheterrelated thrombosis appears to be greatest with femoral venous catheters, followed by those placed in the internal jugular vein, with the least risk reported for subclavian venous catheters. [59] [60] [61] The risk of thrombosis is documented to be 4-fold greater with internal jugular lines as compared with subclavian vein catheters. 60 Recognized predisposing factors for venous thrombosis include catheter-related factors (indwelling time, diameter, CVC material), procedural factors (difficult or traumatic insertion), and patient factors (insertion site, blood viscosity, activation of coagulation factors as a result of the underlying disease). 22, 61 In this study, there was no clinical evidence of catheter-related thrombosis in any of the patients, despite the majority of the patients having an internal jugular vein insertion site, a minimum of 1 of the predisposing factors, and a mean dwell time well beyond 1 week. The administration of subcutaneous low-molecular-weight heparin as part of the routine management of these patients may have decreased the risk of clinically apparent thrombus formation.
Experience with insertion technique has been identified as an important risk for CVC-related BSI. 23, 62 Studies have shown that intensified training and educational programs can substantially reduce the baseline risk of CRBSI. 63, 64 This study was performed in an academic training unit with a large turnover of junior staff, many of whom were involved in catheter placement. This, in conjunction with the background severity of illness of the patients involved, may have been contributing factors to the documented CRIs. All the patients in this study had at least 1 major organ failure and were initially assessed to be likely to spend a substantial amount of time in ICU and hospital and thus be potential candidates for 14-day catheter dwell time.
Subsequent to this study, we have developed a dedicated policy regarding the insertion, maintenance, and use of CVCs. The basic principle revolves around strict adherence to aseptic technique at all times and has been described in recent reviews. [65] [66] [67] It is currently our policy to leave standard CVCs in situ for up to 14 days in critically ill patients, after which time the device is replaced and resited. Since the introduction of this practice and with ongoing repetitive education, it is now the exception that a CVC is removed for suspected CRI.
Epidemiologically, the most common source of primary CRBSI was skin followed by hub and infusate. No difference could be demonstrated between the 2 catheters. These findings are similar to those previously reported.
Conclusions
In this study, no significant difference in CRI rates between standard and CSS-impregnated CVCs could be demonstrated. Standard CVCs can safely be left in situ in critically ill patients for up to 12 days and probably 14 days, with appropriate infection control measures. The most common source of CRI was the skin. Administration of parenteral nutrition and the site of catheter insertion (subclavian vein vs internal jugular vein) were not noted to be risk factors for CRI. Furthermore, there was no clinical evidence of catheterrelated thrombosis in any of the patients.
The data and observations presented in this study are important and offer direction for the use of CVCs in critically ill patients, particularly in light of the many controversies that exist and also in view of the suggestions by various workers in the field that more data on the subject are required. 68 
